Novo Nordisk warns EU that new rules will push it to expand faster in US

Novo Nordisk, Europe’s most valuable drugmaker, will accelerate its US expansion at the expense of the EU unless Brussels changes a plan to reform regulation of the industry, the company’s chief executive has said.